The global Genomic Testing in Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Genomic Testing in Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Genomic Testing in Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Genomic Testing in Cancer in General Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Genomic Testing in Cancer include 23andMe, Agilent Technologies, Bio-Rad Laboratories, Centogene, Color Genomics, Gene By Gene, Illumina, LabCorp and Myriad Genetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Genomic Testing in Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genomic Testing in Cancer.
Report Scope
The Genomic Testing in Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Genomic Testing in Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genomic Testing in Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
23andMe
Agilent Technologies
Bio-Rad Laboratories
Centogene
Color Genomics
Gene By Gene
Illumina
LabCorp
Myriad Genetics
Positive Bioscience
Quest Diagnostics
Thermo Fisher Scientific
Segment by Type
Breast Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Stomach Cancer
Others
Segment by Application
General Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Genomic Testing in Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Genomic Testing in Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Breast Cancer
1.2.3 Lung Cancer
1.2.4 Blood Cancer
1.2.5 Liver Cancer
1.2.6 Stomach Cancer
1.2.7 Others
1.3 Market by Application
1.3.1 Global Genomic Testing in Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 General Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Genomic Testing in Cancer Market Perspective (2019-2030)
2.2 Genomic Testing in Cancer Growth Trends by Region
2.2.1 Global Genomic Testing in Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Genomic Testing in Cancer Historic Market Size by Region (2019-2024)
2.2.3 Genomic Testing in Cancer Forecasted Market Size by Region (2025-2030)
2.3 Genomic Testing in Cancer Market Dynamics
2.3.1 Genomic Testing in Cancer Industry Trends
2.3.2 Genomic Testing in Cancer Market Drivers
2.3.3 Genomic Testing in Cancer Market Challenges
2.3.4 Genomic Testing in Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genomic Testing in Cancer Players by Revenue
3.1.1 Global Top Genomic Testing in Cancer Players by Revenue (2019-2024)
3.1.2 Global Genomic Testing in Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Genomic Testing in Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Genomic Testing in Cancer Revenue
3.4 Global Genomic Testing in Cancer Market Concentration Ratio
3.4.1 Global Genomic Testing in Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genomic Testing in Cancer Revenue in 2023
3.5 Genomic Testing in Cancer Key Players Head office and Area Served
3.6 Key Players Genomic Testing in Cancer Product Solution and Service
3.7 Date of Enter into Genomic Testing in Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Genomic Testing in Cancer Breakdown Data by Type
4.1 Global Genomic Testing in Cancer Historic Market Size by Type (2019-2024)
4.2 Global Genomic Testing in Cancer Forecasted Market Size by Type (2025-2030)
5 Genomic Testing in Cancer Breakdown Data by Application
5.1 Global Genomic Testing in Cancer Historic Market Size by Application (2019-2024)
5.2 Global Genomic Testing in Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Genomic Testing in Cancer Market Size (2019-2030)
6.2 North America Genomic Testing in Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Genomic Testing in Cancer Market Size by Country (2019-2024)
6.4 North America Genomic Testing in Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Genomic Testing in Cancer Market Size (2019-2030)
7.2 Europe Genomic Testing in Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Genomic Testing in Cancer Market Size by Country (2019-2024)
7.4 Europe Genomic Testing in Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genomic Testing in Cancer Market Size (2019-2030)
8.2 Asia-Pacific Genomic Testing in Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Genomic Testing in Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Genomic Testing in Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Genomic Testing in Cancer Market Size (2019-2030)
9.2 Latin America Genomic Testing in Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Genomic Testing in Cancer Market Size by Country (2019-2024)
9.4 Latin America Genomic Testing in Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genomic Testing in Cancer Market Size (2019-2030)
10.2 Middle East & Africa Genomic Testing in Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Genomic Testing in Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Genomic Testing in Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 23andMe
11.1.1 23andMe Company Detail
11.1.2 23andMe Business Overview
11.1.3 23andMe Genomic Testing in Cancer Introduction
11.1.4 23andMe Revenue in Genomic Testing in Cancer Business (2019-2024)
11.1.5 23andMe Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Detail
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Genomic Testing in Cancer Introduction
11.2.4 Agilent Technologies Revenue in Genomic Testing in Cancer Business (2019-2024)
11.2.5 Agilent Technologies Recent Development
11.3 Bio-Rad Laboratories
11.3.1 Bio-Rad Laboratories Company Detail
11.3.2 Bio-Rad Laboratories Business Overview
11.3.3 Bio-Rad Laboratories Genomic Testing in Cancer Introduction
11.3.4 Bio-Rad Laboratories Revenue in Genomic Testing in Cancer Business (2019-2024)
11.3.5 Bio-Rad Laboratories Recent Development
11.4 Centogene
11.4.1 Centogene Company Detail
11.4.2 Centogene Business Overview
11.4.3 Centogene Genomic Testing in Cancer Introduction
11.4.4 Centogene Revenue in Genomic Testing in Cancer Business (2019-2024)
11.4.5 Centogene Recent Development
11.5 Color Genomics
11.5.1 Color Genomics Company Detail
11.5.2 Color Genomics Business Overview
11.5.3 Color Genomics Genomic Testing in Cancer Introduction
11.5.4 Color Genomics Revenue in Genomic Testing in Cancer Business (2019-2024)
11.5.5 Color Genomics Recent Development
11.6 Gene By Gene
11.6.1 Gene By Gene Company Detail
11.6.2 Gene By Gene Business Overview
11.6.3 Gene By Gene Genomic Testing in Cancer Introduction
11.6.4 Gene By Gene Revenue in Genomic Testing in Cancer Business (2019-2024)
11.6.5 Gene By Gene Recent Development
11.7 Illumina
11.7.1 Illumina Company Detail
11.7.2 Illumina Business Overview
11.7.3 Illumina Genomic Testing in Cancer Introduction
11.7.4 Illumina Revenue in Genomic Testing in Cancer Business (2019-2024)
11.7.5 Illumina Recent Development
11.8 LabCorp
11.8.1 LabCorp Company Detail
11.8.2 LabCorp Business Overview
11.8.3 LabCorp Genomic Testing in Cancer Introduction
11.8.4 LabCorp Revenue in Genomic Testing in Cancer Business (2019-2024)
11.8.5 LabCorp Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Detail
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Genomic Testing in Cancer Introduction
11.9.4 Myriad Genetics Revenue in Genomic Testing in Cancer Business (2019-2024)
11.9.5 Myriad Genetics Recent Development
11.10 Positive Bioscience
11.10.1 Positive Bioscience Company Detail
11.10.2 Positive Bioscience Business Overview
11.10.3 Positive Bioscience Genomic Testing in Cancer Introduction
11.10.4 Positive Bioscience Revenue in Genomic Testing in Cancer Business (2019-2024)
11.10.5 Positive Bioscience Recent Development
11.11 Quest Diagnostics
11.11.1 Quest Diagnostics Company Detail
11.11.2 Quest Diagnostics Business Overview
11.11.3 Quest Diagnostics Genomic Testing in Cancer Introduction
11.11.4 Quest Diagnostics Revenue in Genomic Testing in Cancer Business (2019-2024)
11.11.5 Quest Diagnostics Recent Development
11.12 Thermo Fisher Scientific
11.12.1 Thermo Fisher Scientific Company Detail
11.12.2 Thermo Fisher Scientific Business Overview
11.12.3 Thermo Fisher Scientific Genomic Testing in Cancer Introduction
11.12.4 Thermo Fisher Scientific Revenue in Genomic Testing in Cancer Business (2019-2024)
11.12.5 Thermo Fisher Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
23andMe
Agilent Technologies
Bio-Rad Laboratories
Centogene
Color Genomics
Gene By Gene
Illumina
LabCorp
Myriad Genetics
Positive Bioscience
Quest Diagnostics
Thermo Fisher Scientific
*If Applicable.